HSD3B1 genotype and abiraterone metabolism in patients with prostate cancer

被引：0
|
作者：
Alyamani, Mohammad [1 ]
Emamekhoo, Hamid [2 ]
Park, Sunho [1 ]
Taylor, Jennifer [1 ]
Almassi, Nima [1 ]
Upadhyay, Sunil [3 ]
Tyler, Allison [1 ]
Berk, Michael P. [1 ]
Hwang, Tae Hyun [1 ]
Grivas, Petros [1 ]
Rini, Brian [1 ]
Garcia, Jorge [1 ]
Auchus, Richard J. [3 ]
Sharifi, Nima [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[3] Univ Michigan, Sch Med, Ann Arbor, MI USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2572
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT
    Handy, Whitney F.
    Schmidt, Keith T.
    Price, Douglas K.
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2020, 21 (09) : 782 - 784
  • [32] MISSENSE POLYMORPHISM IN SRD5A2 IN COMBINATION WITH HSD3B1 VARIATION IS ASSOCIATED WITH OUTCOME OF CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE
    Shiota, Masaki
    Akamatsu, Shunsuke
    Narita, Shintaro
    Sumiyoshi, Takayuki
    Fujiwara, Maki
    Uchiumi, Takeshi
    Ogawa, Osamu
    Habuchi, Tomonori
    Eto, Masatoshi
    JOURNAL OF UROLOGY, 2020, 203 : E122 - E122
  • [33] Response prediction with HSD3B1
    Clemens Thoma
    Nature Reviews Urology, 2017, 14 : 699 - 699
  • [34] The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer
    Masaki Shiota
    Shusuke Akamatsu
    Shintaro Narita
    Takayuki Sumiyoshi
    Maki Fujiwara
    Takeshi Uchiumi
    Osamu Ogawa
    Tomonori Habuchi
    Masatoshi Eto
    The Pharmacogenomics Journal, 2021, 21 : 440 - 445
  • [35] Impact of a mutation in HSD3B1 gene on the effectiveness of androgenic deprivation treatment in prostate cancer
    Martin-Abreu, C. M.
    Ramos-Diaz, R.
    Mourani-Padron, I.
    Del Rosario-Garcia, B.
    Garcia-Marrero, R. D.
    Plata-Bello, A. C.
    Nazco-Casariego, G. J.
    Gutierrez-Nicolas, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S533 - S533
  • [36] Variant Allele of HSD3B1 Increases Progression to Castration-Resistant Prostate Cancer
    Wu, Gang
    Huang, Shengsong
    Nastiuk, Kent L.
    Li, Jinliang
    Gu, Jun
    Wu, Ming
    Zhang, Qimin
    Lin, Hanqing
    Wu, Denglong
    PROSTATE, 2015, 75 (07): : 777 - 782
  • [37] Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer
    Hearn, Jason W. D.
    Xie, Wanling
    Nakabayashi, Mari
    Almassi, Nima
    Reichard, Chad A.
    Pomerantz, Mark
    Kantoff, Philip W.
    Sharifi, Nima
    JAMA ONCOLOGY, 2018, 4 (04) : 558 - 562
  • [38] HSD3B1 polymorphism in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP): Pharmacodynamics and therapeutic implications.
    Bastos, Diogo Assed
    Camargo, Anamaria Aranha
    Zylberberg, Ricardo
    Fontes Jardim, Denis Leonardo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [39] The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer
    Shiota, Masaki
    Akamatsu, Shusuke
    Narita, Shintaro
    Sumiyoshi, Takayuki
    Fujiwara, Maki
    Uchiumi, Takeshi
    Ogawa, Osamu
    Habuchi, Tomonori
    Eto, Masatoshi
    PHARMACOGENOMICS JOURNAL, 2021, 21 (04): : 440 - 445
  • [40] PHARMACOGENOMIC DETERMINANTS OF SERUM STEROID HORMONE RESPONSES TO ABIRATERONE OR ENZALUTAMIDE AND HSD3B1 GENE MUTATION IN CRPC PATIENTS
    Serag, Hosam
    Chen, Emilia
    Adomat, Hans
    Khalaf, Daniel
    Wyatt, Alexander
    Gleave, Martin
    JOURNAL OF UROLOGY, 2021, 206 : E736 - E737
12345